Evaluation Of Biochemical and Endocrine Biomarkers Along with Pulmonary Function Tests in Patients with Polycystic Ovarian Syndrome: A Meta-Analysis

Authors

  • Razia Mehsud Department of Obstetrics and Gynaecology, Kohat Institute of Medical Sciences/Liaqat Memorial Hospital, Kohat - Pakistan
  • Chaman Ara Department of Gynaecology and Obstetrics, Women Medical and Dental College, Abbottabad - Pakistan
  • Fahad Sarfraz Medical Education Department, Sahara Medical College, Narowal - Pakistan
  • Isma Rauf Department of Obstetrics and Gynaecology, Women Medical College, Abbottabad - Pakistan
  • Beenish Samreen Hamid Department of Obstetrics and Gynaecology, Kohat Institute of Medical Sciences/Liaqat Memorial Hospital, Kohat - Pakistan
  • Maaz Ullah Department of Biochemistry, Jinnah Medical College, Peshawar - Pakistan

Keywords:

Obesity, FSH, Androgen Index, CRP, FEV1, FVC, OSA Severity

Abstract

Background: Some publications have pointed to the possibility that polycystic ovarian syndrome (PCOS) is associated with pulmonary dysfunction, but the nature of this association is not fully understood yet. The purpose of this research is to determine the the relationship between inflammatory biomarkers and lung function in women affected by PCOS. Objective: To determine the correlation between the biochemical and endocrine biomarkers and the pulmonary function test in women with PCOS. Methodology: The research was carried out in PubMed, MEDLINE, Scopus, Web of Science, and Embase databases without date restrictions up to 2021. In the search, both observational studies and clinical trials have been included and focused on biochemical biomarkers (such as insulin, glucose, CRP, and IL-6), endocrine biomarkers (including LH/FSH ratio and cortisol), and pulmonary function tests (e.g., FEV and FVC) in women with PCOS. The data were analyzed using meta-analytic methods, with the qualitative subgroups based on a study design and geographical location discussed. Results: We identified that women with PCOS have an increased inflammatory index of biomarkers, including CRP (+3. 8 mg/L, p<0. 001), IL-6 (+2. Pulmonary function tests highlighted a trend in decreased FVC and FEV1 (FVC-0. 25 L, p=0. 005, FEV1 -0. 32 L, p=0.Conclusion: By using inflammatory markers as predictors, this work shows that women with PCOS present poor lung function. Taken together these results imply that inflammation is a significant factor in PCOS respiratory consequences, and the process should be further studied with reference to potential remedial measures. Conclusion: This meta-analysis has provided certain evidence to the findings that many circulatory biochemical markers like MMP-7, SP-D, and IL-6 are significantly correlated with the decline in pulmonary function of IPF patients. These results support the conclusions of other investigations and indicate that these markers might be used as informative predictors.

References

Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2(1):1-18.

Ortiz-Flores AE, Luque-Ramírez M, Escobar-Morreale HF. Polycystic ovary syndrome in adult women. Med Clin (Engl Ed). 2019;152(11):450-7.

Bozdag G, Mumusoglu S, Coskun ZY, Yarali H, Yildiz BO. Anti-Müllerian hormone as a diagnostic tool for PCOS under different diagnostic criteria in an unselected population. Reprod Biomed Online. 2019;39(3):522-9.

Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270-84.

Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev. 2015;36(5):487-525.

Rodriguez Paris V. Impact of hyperandrogenism and diet on the development of polycystic ovary syndrome: UNSW Sydney; 2020.

Deepashree D. To Study the Utility of Complete Repertory in the Management of Polycystic Ovarian Syndrome: Rajiv Gandhi University of Health Sciences (India); 2017.

Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E. American Association of Clinical Endocrinologists, American College of Endocrinology, and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome-part 1. Endocr Pract. 2015;21(11):1291-300.

Wang J, Wu D, Guo H, Li M. Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome. Life Sci. 2019;236:116940.

Maqbool M, Dar MA, Gani I, Geer MI. Insulin resistance and polycystic ovary syndrome: a review. J Drug Deliv Ther. 2019;9(1-s):433-6.

Izaguirre M, Gil MJ, Monreal I, Montecucco F, Frühbeck G, Catalán V. The role and potential therapeutic implications of the fibroblast growth factors in energy balance and type 2 diabetes. Curr Diab Rep. 2017;17:1-14.

Ibrahim TAE-S, Ali AE-S, Radwan ME-H. Lipid profile in women with polycystic ovary syndrome. Egypt J Hosp Med. 2020;78(2):272-7.

Liu Q, Xie Y-J, Qu L-H, Zhang M-X, Mo Z-C. Dyslipidemia involvement in the development of polycystic ovary syndrome. Taiwan J Obstet Gynecol. 2019;58(4):447-53.

Underdal MO, Salvesen Ø, Henriksen AH, Andersen M, Vanky E. Impaired respiratory function in women with PCOS compared with matched controls from a population-based study. J Clin Endocrinol Metab. 2020;105(1):344-54.

Real FG, Svanes C, Omenaas ER, Antò JM, Plana E, Janson C, et al. Menstrual irregularity and asthma and lung function. J Allergy Clin Immunol. 2007;120(3):557-64.

Campbell B, Davis S, Abramson M, Mishra G, Handelsman D, Perret J, et al. Menopause, lung function and obstructive lung disease outcomes: a systematic review. Climacteric. 2018;21(1):3-12.

Lencu C, Alexescu T, Petrulea M, Lencu M. Respiratory manifestations in endocrine diseases. Clujul Med. 2016;89(4):459.

Mafort TT, Rufino R, Costa CH, Lopes AJ. Obesity: systemic and pulmonary complications, biochemical abnormalities, and impairment of lung function. Multidiscip Respir Med. 2016;11:1-11.

Yanes Cardozo LL, Rezq S, Pruett JE, Garla VV, Romero DG. Androgen Excess in Women and the Respiratory System. Sex-Based Differences in Lung Physiol. 2021:405-28.

Yaman FK, Arslan S. Effects of progesterone treatment in polycystic ovary syndrome on pulmonary functions. Turk Hij Den Biyol Derg. 2019.

Palomba S, Santagni S, Falbo A, La Sala GB. Complications and challenges associated with polycystic ovary syndrome: current perspectives. Int J Womens Health. 2015:745-63.

Rocha AL, Oliveira FR, Azevedo RC, Silva VA, Peres TM, Candido AL, et al. Recent advances in the understanding and management of polycystic ovary syndrome. F1000Res. 2019;8.

Jamil Z, Fatima SS, Ahmed K, Malik R. Anti-Mullerian hormone: above and beyond conventional ovarian reserve markers. Dis Markers. 2016;2016(1):5246217.

Iwase A, Osuka S, Goto M, Murase T, Nakamura T, Takikawa S, et al. Clinical application of serum anti-Müllerian hormone as an ovarian reserve marker: a review of recent studies. J Obstet Gynaecol Res. 2018;44(6):998-1006.

Moolhuijsen LM, Visser JA. Anti-Müllerian hormone and ovarian reserve: update on assessing ovarian function. J Clin Endocrinol Metab. 2020;105(11):3361-73.

Greydanus DE, Agana M, Kamboj MK, Shebrain S, Soares N, Eke R, et al. Pediatric obesity: Current concepts. Dis Mon. 2018;64(4):98-156.

Cardinali DP, Rai S, Spinedi E. Melatonin as a Possible Chronobiotic/Cytoprotective Therapy in Polycystic Ovarian Syndrome. Herbal Medicine Applications for Polycystic Ovarian Syndrome: CRC Press. p. 301-26.

Hamai K, Iwamoto H, Ishikawa N, Horimasu Y, Masuda T, Miyamoto S, et al. Comparative study of circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as disease markers of idiopathic pulmonary fibrosis. Dis Markers. 2016;2016(1):4759040.

Papiris SA, Tomos IP, Karakatsani A, Spathis A, Korbila I, Analitis A, et al. High levels of IL-6 and IL-8 characterize early-on idiopathic pulmonary fibrosis acute exacerbations. Cytokine. 2018;102:168-72.

Zhang T, Shen P, Duan C, Gao L. KL-6 as an immunological biomarker predicts the severity, progression, acute exacerbation, and poor outcomes of interstitial lung disease: a systematic review and meta-analysis. Front Immunol. 2021;12:745233.

De Gramont A, Watson S, Ellis LM, Rodón J, Tabernero J, De Gramont A, et al. Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat Rev Clin Oncol. 2015;12(4):197-212.

Adegunsoye A, Alqalyoobi S, Linderholm A, Bowman WS, Lee CT, Pugashetti JV, et al. Circulating plasma biomarkers of survival in antifibrotic-treated patients with idiopathic pulmonary fibrosis. Chest. 2020;158(4):1526-34.

Zheng P, Zheng X, Takehiro H, Cheng ZJ, Wang J, Xue M, et al. The prognostic value of Krebs von den Lungen-6 and surfactant protein-A levels in the patients with interstitial lung disease. J Transl Intern Med. 2021;9(3):212-22.

Aarsand AK, Røraas T, Fernandez-Calle P, Ricos C, Díaz-Garzón J, Jonker N, et al. The biological variation data critical appraisal checklist: a standard for evaluating studies on biological variation. Clin Chem. 2018;64(3):501-14.

Downloads

Published

2022-03-02

How to Cite

Mehsud, R. ., Ara, C. ., Sarfraz, F. ., Rauf, I. ., Hamid, B. S. ., & Ullah, M. . (2022). Evaluation Of Biochemical and Endocrine Biomarkers Along with Pulmonary Function Tests in Patients with Polycystic Ovarian Syndrome: A Meta-Analysis. Pakistan Journal of Chest Medicine, 28(1), 115–121. Retrieved from https://www.pjcm.net/index.php/pjcm/article/view/857

Issue

Vol. 28 No. 1 (2022)

Section

Review Article

License

Copyright (c) 2022 Pakistan Journal of Chest Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Most read articles by the same author(s)